Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by
Crossref.
Strupczewski, June D.
and
Ellis, Daniel B.
1992.
Vol. 27,
Issue. ,
p.
321.
Power, A. C.
and
Cowen, P. J.
1992.
Fluoxetine and Suicidal Behaviour.
British Journal of Psychiatry,
Vol. 161,
Issue. 6,
p.
735.
Edwards, J. G.
1992.
Selective serotonin reuptake inhibitors..
BMJ,
Vol. 304,
Issue. 6843,
p.
1644.
De Wilde, J.
Spiers, R.
Mertens, C.
Bartholomé, F.
Schotte, G.
and
Leyman, S.
1993.
A double‐blind, comparative, multicentre study comparing paroxetine with fluoxetine in depressed patients.
Acta Psychiatrica Scandinavica,
Vol. 87,
Issue. 2,
p.
141.
Nelson, David R.
Palmer, Katherine J.
Tasker, Timothy C. G.
and
Tulloch, Ian F.
1993.
Neurochemical evidence that the antidepressant paroxetine is a selective serotonin reuptake inhibitor in man.
Depression,
Vol. 1,
Issue. 5,
p.
263.
Edwards, J. Guy
and
Goldie, Ann
1993.
Placebo‐Controlled trial of paroxetine in depressive illness.
Human Psychopharmacology: Clinical and Experimental,
Vol. 8,
Issue. 3,
p.
203.
Sheldon, Trevor A
Freemantle, Nick
House, Allan
Adams, Clive E.
Mason, James M.
Song, Fujian
Long, Andrew
and
Watson, Paul
1993.
Examining the effectiveness of treatments for depression in general practice.
Journal of Mental Health,
Vol. 2,
Issue. 2,
p.
141.
Cookson, John
1993.
Side-effects of Antidepressants.
British Journal of Psychiatry,
Vol. 163,
Issue. S20,
p.
20.
Laux, G.
Delini-Stula, A.
Breyer-Pfaff, U.
Demling, J.
Ebert, D.
Pöldinger, W.
Kasper, S.
Osterheider, M.
Dietmaier, O.
Möller, H.-J.
and
Fuger, J.
1993.
Neuro-Psychopharmaka.
p.
105.
Dunner, DL
and
Dunbar, GC
1993.
Managing the patient with depression and anxiety.
European Psychiatry,
Vol. 8,
Issue. S1,
p.
9s.
Montgomery, SA
1993.
A review of the safety of paroxetine.
European Psychiatry,
Vol. 8,
Issue. S1,
p.
25s.
McFarland, Bentson H.
1994.
Cost-effectiveness considerations for managed care systems: Treating depression in primary care.
The American Journal of Medicine,
Vol. 97,
Issue. 6,
p.
S47.
Feighner, J. P.
1994.
Compliance and quality of response are major contributors to cost-effective antidepressant therapy.
Human Psychopharmacology: Clinical and Experimental,
Vol. 9,
Issue. S1,
p.
S21.
Anderson, I.M.
and
Tomenson, B.M.
1994.
The efficacy of selective serotonin re-uptake inhibitors in depression: a meta-analysis of studies against tricyclic antidepressants.
Journal of Psychopharmacology,
Vol. 8,
Issue. 4,
p.
238.
Nelson, J Craig
1994.
Are the SSRIs Really Better Tolerated Than the TCAs for Treatment of Major Depression?.
Psychiatric Annals,
Vol. 24,
Issue. 12,
p.
628.
Kasper, S.
Lepine, J. P.
Mendlewicz, J.
Montgomery, S. A.
and
Rush, A. John
1994.
Efficacy, safety, and indications for tricyclic and newer antidepressants.
Depression,
Vol. 2,
Issue. 3,
p.
127.
Lightowler, S.
Kennett, G.A.
Williamson, I.J.R.
Blackburn, T.P.
and
Tulloch, I.F.
1994.
Anxiolytic-like effect of paroxetine in a rat social interaction test.
Pharmacology Biochemistry and Behavior,
Vol. 49,
Issue. 2,
p.
281.
Montgomery, Stuart A.
1994.
Clinically relevant effect sizes in depression.
European Neuropsychopharmacology,
Vol. 4,
Issue. 3,
p.
283.
Freemantle, Nick
and
Maynard, Alan
1994.
Something rotten in the state of clinical and economic evaluations?.
Health Economics,
Vol. 3,
Issue. 2,
p.
63.
Jönsson, Bengt
and
Bebbington, Paul E.
1994.
What Price Depression?.
British Journal of Psychiatry,
Vol. 164,
Issue. 5,
p.
665.
eLetters
No eLetters have been published for this article.